Prognostic Value of BNP in MCS - a 25 Year Follow up Study
Condition(s) studied
Investigational drug(s) / intervention(s)
Observation. No intervention per se.: Observation. No intervention (no collection of blood).
2) Observation and collection and of blood sample: All patients evaluated for adv HF (HTX/LVAD) will be offered to contribute to this database; Blood samples will be collected from all at baseline. Patients receiving LVAD will contribute on a yearly basis (or until withdrawal of consent). For other patients no further blood will be collected unless they receive an LVAD at a later point.
Study summary
A biobank has been created to investigate the prognostic value of biomarkers (mainly BNP) in patients implanted with durable mechanical assist devices comparing patients with advanced HF supported by MCS with those who are transplanted and those who remain on optimal medical therapy.
Patients will be followed up for 25 years after inclusion.
Eligibility
Primary outcome measure(s)
- Alive — 25 years from inclusion
- Dead — 25 years from inclusion
Dead after inclusion in study
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Rigshospitalet | Copenhagen | DK | Recruiting |
More Copenhagen University Hospital, Rigshospitalet trials in Denmark
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT04377854 on ClinicalTrials.gov ↗ ← All trials in Denmark